JATT III Acquisition Corp closed its initial public offering of 6,900,000 ordinary shares at $10.00 each on Aug. 27, 2026, generating $69 million in gross proceeds before underwriting discounts, commissions and other offering expenses. The shares began trading on the Nasdaq Global Market under the ticker JTTT on Aug. 26. The Cayman Islands blank-check company has no selected business-combination target and plans to focus primarily on biotechnology and broader life sciences, including businesses using machine learning, computational biology, structure-based drug design and related technologies. AI Biotechnology LLC and Vianti Capital Fund I, L.P. have indicated non-binding interest in a possible private placement concurrent with a future business combination. Guggenheim Securities, LLC acted as sole book-running manager, and the company said the IPO and any eventual business combination remain subject to risks and uncertainty.